← Back to Search

Conjugate Vaccine

24-Valent Pneumococcal Conjugate Vaccine for Pneumococcal Vaccines

Phase 2

Waitlist Available

Research Sponsored by Vaxcyte, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 7 days after vaccination

Awards & highlights

Study Summary

This trial is testing a new vaccine against pneumococcus bacteria in adults 65 and older, to see if it is safe and tolerated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 7 days after vaccination

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~7 days after vaccination

This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days after vaccination for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percentage of participants reporting SAEs and new onset of chronic illnesses (NOCIs)

Percentage of participants reporting solicited local reactions within 7 days after vaccination

Percentage of participants reporting solicited systemic events within 7 days after vaccination

+1 more

Secondary outcome measures

24 VAX-24 Pneumococcal serotype-specific IgG geometric mean concentration (GMCs)

24 VAX-24 Pneumococcal serotype-specific opsonophagocytic assay (OPA) geometric mean titer (GMTs)

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Group 3Experimental Treatment1 Intervention

Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.

Group II: Group 2Experimental Treatment1 Intervention

Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.

Group III: Group 1Experimental Treatment1 Intervention

Participants will receive a single dose of VAX-24 administered as an intramuscular injection on Day 1 at one of three dose levels.

Group IV: Group 4Active Control1 Intervention

Participants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

24-Valent Pneumococcal Conjugate Vaccine

2022

Completed Phase 2

~210

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Vaxcyte, Inc.Lead Sponsor

3 Previous Clinical Trials

2,586 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any patients currently enrolled in this trial?

"Unfortunately, as of September 12th 2022, this clinical trial is no longer looking for candidates. This is according to the latest update on clinicaltrials.gov. Although this particular study may be full, there are 5 other active trials that patients can participate in."

Answered by AI

Could you please outline the risks associated with 24-Valent Pneumococcal Conjugate Vaccine?

"24-Valent Pneumococcal Conjugate Vaccine is still being studied in Phase 2 clinical trials. So far, there is supporting evidence for safety but not efficacy."

Answered by AI

Is this clinical trial underway in several hospitals across North America?

"Presently, this clinical trial is looking for participants from 21 different medical centres. If you are interested in enrolling, it would be advantageous to choose a location near to reduce travel. The sites are located in Birmingham, Mount Pleasant and DeLand among other cities."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

2022. "Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05297578.